甲烷胺哌嗪-2,1-甲基-(9CI) | 131922-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 甲烷胺哌嗪-2,1-甲基-(9CI)
• 中文别名: 1-甲基-2-哌嗪甲胺；(1-甲基哌嗪-2-基)甲胺
• 英文名称: (1-methylpiperazin-2-yl)methanamine
• CAS: 131922-03-7
• 化学式: C₆H₁₅N₃
• mdl: MFCD18072987
• 分子量: 129.205
• InChiKey: QVRTZAUDSGLLQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  7-氮杂吲哚-3-甲醛 、 甲烷胺哌嗪-2,1-甲基-(9CI) 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  发现具有可调异构体选择性的强效和高选择性激酶 CK1 抑​​制剂

  摘要：

  新发现的化学生物学探针MU1250、MU1500和MU1742，基于 1 H-吡咯并[2,3- b ]吡啶-咪唑支架，允许高度特异性靶向细胞中的亚型 CK1α、CK1δ 和 CK1ε体内。我们的观察表明，中央支架可以更广泛地用于靶向其他蛋白激酶的化合物，高选择性 p38α 抑制剂MU1299证明了这一点。

  DOI：

  10.1002/anie.202217532

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• METHOD FOR PRODUCING AMINES FROM GLYCERIN
  申请人：Ernst Martin

  公开号：US20100240894A1

  公开（公告）日：2010-09-23

  The present invention relates to a process for preparing amines by reacting glycerol with hydrogen and an aminating agent from the group of ammonia and primary and secondary amines in the presence of a catalyst at a temperature of from 100° C. to 400° C. and a pressure of from 0.01 to 40 MPa (from 0.1 to 400 bar). Preference is given to using glycerol based on renewable raw materials. The catalyst preferably comprises one metal or a plurality of metals or one or more oxygen compounds of the metals of groups 8 and/or 9 and/or 10 and/or 11 of the Periodic Table of the Elements. The invention further relates to the use of the reaction products as an additive in cement or concrete production and in other fields of use. This invention further provides the compounds 1,2,3-triaminopropane, 2-aminomethyl-6-methylpiperazine, 2,5-bis(aminomethyl)piperazine and 2,6-bis(aminomethyl)piperazine.

  本发明涉及一种通过在催化剂存在下，将甘油与氢气和来自氨和一次和二次胺组的氨化剂反应，在温度从100°C至400°C和压力从0.01至40兆帕（从0.1至400巴）条件下制备胺的方法。优选使用基于可再生原料的甘油。催化剂优选包括元素周期表第8和/或9和/或10和/或11族金属或多种金属或这些金属的一个或多个氧化物。该发明还涉及将反应产物用作水泥或混凝土生产中的添加剂以及其他用途领域。该发明还提供了化合物1,2,3-三胺丙烷，2-氨基甲基-6-甲基哌嗪，2,5-双(氨基甲基)哌嗪和2,6-双(氨基甲基)哌嗪。
• [EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
  申请人：SEARLE & CO

  公开号：WO2000031063A1

  公开（公告）日：2000-06-02

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。 特别感兴趣的化合物由公式（IA）定义，其中R?1，R2，R3和R4¿如规范中所述。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。
• Five-membered heterocyclic derivative
  申请人：Okayama Toru

  公开号：US20060189591A1

  公开（公告）日：2006-08-24

  The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.

  本发明涉及一种由公式（I）表示的化合物：该化合物的盐，或该化合物或盐的溶剂化物；含有任何该化合物、盐和溶剂化物的药物；含有任何该化合物、盐和溶剂化物的缺血性疾病的预防和/或治疗剂；以及含有任何该化合物、盐和溶剂化物的血小板凝集抑制剂。本发明的化合物在不抑制COX-1或COX-2的情况下作为强效的血小板凝集抑制剂非常有用。